Logo

AbbVie Signs Two Option and License Agreements with Umoja Biopharma to Develop CAR-T Cell Therapies for Hematologic Malignancies

Share this
AbbVie

AbbVie Signs Two Option and License Agreements with Umoja Biopharma to Develop CAR-T Cell Therapies for Hematologic Malignancies

Shots:

  • As per the 1st agreement, AbbVie receives an exclusive option to license Umoja's CD19 directed in-situ generated CAR-T cell therapy candidates incl. UB-VV111 for hematologic malignancies (in IND-enabling phase)
  • As per the 2nd agreement, AbbVie & Umoja will jointly develop up to four additional in-situ generated CAR-T cell therapy candidates for targets selected by AbbVie by using Umoja’s VivoVec gene delivery platform
  • Under the terms of both agreements, Umoja will receive an up front payment along with equity investments & is eligible to receive an aggregate of up to $1.44B for option exercise fees, development & regulatory milestones with the potential to earn additional sales-based milestones plus tiered royalties

Ref: AbbVie | Image: AbbVie

Related News:- Umoja Biopharma Entered into a Research Collaboration with IASO Biotherapeutics to Develop Off-the-Shelf Therapies for Hematological Malignancies

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions